• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

    6.110 -0.040 (-0.65%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 73,939
    Open 6.130
    Bid (Size) 6.080 (900)
    Ask (Size) 6.110 (200)
    Prev. Close 6.150
    Today's Range 5.960 - 6.340
    52wk Range 3.280 - 9.821
    Shares Outstanding 41,957,197
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Reports Q4 Earnings Beat and Accelerating Revenue Growth ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire

    Performance

    YTD
    -26.4%
    -26.4%
    1 Month
    +1.3%
    +1.3%
    3 Month
    -26.4%
    -26.4%
    6 Month
    +23.7%
    +23.7%
    1 Year
    +2.0%
    +2.0%

    More News

    Read More
    News headline image
    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    What to Expect from Verrica Pharmaceuticals's Earnings ↗
    Via Benzinga
    News headline image
    Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are gapping on Monday? ↗
    Via Chartmill
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Which stocks are moving on Friday? ↗
    Via Chartmill
    News headline image
    Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Top movers in Friday's pre-market session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Posts Profit in Fiscal Q2 ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For August 12, 2025 ↗
    Via Benzinga

    Frequently Asked Questions

    Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
    Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
    What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
    The current price of Verrica Pharmaceuticals Inc. - Common Stock is 6.110
    When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 03/13/26 03:58 PM ET
    What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
    The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 256.36M
    How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
    Verrica Pharmaceuticals Inc. - Common Stock has 256M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.